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Abstract 
Background: Chlamydia spp. are obligate, intracellular bacteria that infect humans and animals. Research on these 
important pathogens has been hindered due to a paucity of genetic tools. We recently adapted a group II intron 
(GII) mutagenesis platform for creation of ampicillin-selectable gene insertions in C. trachomatis L2. The aims of this 
study were: (1) to assess the stability of the intron-insertion in an in vivo infection model to gauge the efficacy of this 
genetic tool for long term animal studies and (2) to expand upon the utility of the method by validating a second 
selection marker (aadA, conferring spectinomycin resistance) for mutant construction.
Results: Intron stability was assessed using a mouse vaginal tract infection model with a C. trachomatis L2 434/Bu 
incA::GII(bla) mutant. Infections were performed in the absence of selection and isolates shed into the vaginal tract 
were isolated and expanded in cell culture (also without selection). PCR and inclusion phenotype analysis indicated 
that the intron was stable for at least 27 days post-infection (at which point bacteria were no longer recovered from 
the mouse). The aminoglycoside 3′ adenyltransferase (aadA) gene was used to create a spectinomycin-selectable GII 
intron, facilitating the construction of an incA::GII[aadA] C. trachomatis L2 insertion mutant. Both the GII(aadA) intron 
and our previously reported GII(bla) intron were then used to create an incA::GII(aadA), rsbV1::GII(bla) double mutant. 
Mutants were confirmed via PCR, sequencing, inclusion morphology (incA only), and western blot.
Conclusions: The stability of the intron-insertion during in vivo growth indicates that the GII-insertion mutants can 
be used to study pathogenesis using the well-established mouse infection model. In addition, the validation of an 
additional marker for mutagenesis in Chlamydia allows for gene complementation approaches and construction of 
targeted, double mutants in Chlamydia. The aadA marker also could be useful for other genetic methods. Collectively, 
our results expand upon the rapidly growing chlamydial genetic toolkit and will aid in the implementation of studies 
dissecting the contribution of individual genes to infection.
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Background
Chlamydia spp. infect a wide variety of animals and 
cause serious disease in humans including pneumo-
nia, trachoma (an ocular infection), and sexually trans-
mitted infections (STI) [1]. The latter are caused by C. 
trachomatis and represent the most prevalent reportable 
bacterial STI in both the United States and world-wide 
[2, 3]. These obligate, intracellular bacterial pathogens 
have a unique developmental cycle transitioning between 
the extracellular, infectious form known as the elemen-
tary body (EB) and the intracellular, replicative form 
referred to as the reticulate body (RB) [4]. Differentiation 
initiates after cell surface binding and internalization of 
the EB into a host-derived membrane vacuole termed an 
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inclusion. Within the inclusion the EB differentiates into 
the RB, which divide by binary fission. After ~20 h post-
infection, RBs asynchronously differentiate back into EBs 
and after 40–72 h post-infection the EBs escape from the 
cell via cell lysis or inclusion extrusion [5]. Despite their 
significant negative impact on agriculture and human 
health and their intriguing physiology, research on Chla-
mydia had been hindered due to the limited number of 
available genetic tools [6, 7].
In 2011, Wang et al. described a robust chemical trans-
formation protocol and antibiotic-selection conditions 
that enabled the generation of recombinant Chlamydia 
trachomatis [8]. Since this seminal publication, a vari-
ety of recombinant plasmids platforms (based on the 
native chlamydial cryptic plasmid) have been developed 
to enable expression of foreign and recombinant genes 
in Chlamydia spp. [9–16]. In addition, chemical-based 
mutagenesis approaches have been leveraged for use 
in forward and reverse genetic approaches [17–19]. To 
complement these approaches, we recently modified the 
TargeTron mutagenesis system to allow for creation of 
chromosomal gene insertion mutants in Chlamydia tra-
chomatis [20]. This methodology employs a mobile GII 
intron that can be “targeted” to genes of interest by alter-
ing DNA sequences within the 5′ region of the intron via 
PCR-based mutagenesis [21]. This mutagenesis approach 
has been utilized for construction of insertion mutants in 
a variety of Gram-negative and Gram-positive bacteria 
[22].
Our first generation bla-marked intron platform had a 
number of limitations. Firstly, the bla-resistance marker 
may not be used in the C. trachomatis genital serovars 
D-K as β-lactams (as an alternative therapy) are still a 
suggested form of treatment for pregnant women (bla 
is subsequently prohibited for use in these strains by the 
National Institutes of Health Guidelines for Research 
Involving Recombinant DNA Molecules). Secondly, 
use of the bla-marker limits gene complementation 
approaches as the majority of chlamydial shuttle vec-
tors utilize the bla-marker for plasmid selection and 
maintenance. Thirdly, use of a single marker limits the 
number of insertions that may be made in a single bac-
terium. Finally, while the intron appears stable over mul-
tiple passages in cell culture it was unknown whether the 
intron would be stable in the absence of selection in an 
extended-period (~1 month) animal model. To address 
the known limitations and potential problem of in  vivo 
stability, we sought to identify alternative selection mark-
ers and to assess the stability of the intron-insertion in 
a mouse infection model. Validation of new markers for 
use in Chlamydia would expand the growing chlamydial 
molecular tool kit and allow for experiments querying the 
role of specific genes in pathogenesis under conditions 
fulfilling Molecular Koch’s postulates [23]. In addition, 
demonstration of intron-insertion stability in  vivo has 
implications not just for chlamydial research, but also for 
other pathogens in which TargeTron-generated mutants 
are tested in animal models of disease.
Results and discussion
In vivo stability of the intron insertion While cell cul-
ture growth experiments with Chlamydia allow for the 
interrogation of numerous hypotheses, animal infection 
models remain critical for studying innate and adaptive 
immune responses to infection. Previous animal infec-
tion studies with other bacteria carrying GII intron-
insertions have been performed [24–29]. However, to 
the best of our knowledge, intron stability was either not 
assessed in those studies or the study was short term (less 
than 1 week). Prior to developing alternative markers for 
mutant selection in C. trachomatis, we wanted to ensure 
that the intron-insertion would be stable in an animal 
infection model (the primary concern was loss of the 
intron from the marked-gene resulting in reconstitution 
of a wild type genotype).
To measure intron stability, mice were infected vagi-
nally with the IncA-null strain DFCT3 (incA::GII[bla]) 
[20]. IncA is an inclusion membrane protein that medi-
ates the fusion of multiple inclusions into a single 
inclusion (each infecting EB initially resides in its own 
inclusion) [30, 31]. Consequently, cells infected at an 
MOI  >1 with IncA-deficient strains exhibit a non-fuso-
genic inclusion phenotype [20, 31]. DFCT3-infected mice 
were swabbed at 3 day intervals post-infection. Swabs 
were titered using the IFU assay and expanded in cell 
culture for genotype and phenotype analysis (Fig. 1). No 
beta-lactams were used during infection or cell culture 
expansion of swab samples. Detectable levels of EBs were 
shed until day 27 post-infection (Fig. 1a). Intron-presence 
was assessed using PCR with incA-specific primers flank-
ing the intron insertion site. All isolates were positive for 
the intron (representative results are shown in the Fig. 1a 
inset) based upon the presence of only the larger, inser-
tion-positive PCR product (incA-locus map, Fig.  2a). In 
addition, cells infected with the isolates at an MOI of ~5 
formed non-fusogenic inclusions as previously docu-
mented for natural and intron-constructed IncA-null 
strains (Fig.  1b) [20, 31]. These data indicate that the 
intron is stable throughout the course of infection in the 
absence of selection, consistent with results obtained 
from repeated passage of intron-insertion mutants in cell 
culture [as seen with DFCT3, 4, 9, 13, and 16 (this study 
and [20])]. A caveat to the PCR-based approach used for 
assessing incA::GII(bla) stability would be the inability to 
detect large genome arrangements in the mutant strain, 
although this was not a focus of the study. The ability to 
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carry out antibiotic free in vivo experiments is significant 
as antibiotic usage alters the normal microflora, which 
can lead to invalid results.
Validation of the aadA gene as a selection marker 
in C. trachomatis After demonstrating stability of the 
intron-insertion in vivo, we searched for additional drug 
resistance markers to: (1) allow for the use of TargeTron 
outside of the LGV serovar (the NIH prohibits the use of 
bla in C. trachomatis serovars D-K), (2) permit comple-
mentation of mutants using the bla-based shuttle vectors 
(bsd and cat-based vectors are available, but these vec-
tors are not as numerous or well-studied as the bla-based 
vectors), and (3) allow for construction of mutants with 
multiple gene disruptions. To test alternative markers, 
the bla cassette was removed from the intron in pDFTT3 
and replaced with either cat (chloramphenicol resist-
ance), arr-2 (rifampin resistance), or aadA (spectinomy-
cin resistance). All introns remained targeted to incA.
Mutagenesis was attempted at least four times using 
the appropriate antibiotic/intron combination. Experi-
ments with the GII(cat) construct resulted in no mutants 
and experiments with the GII(arr-2) construct only 
yielded spontaneous rifampin-resistant mutants (data 
not shown). Rifr strains were not sequenced for muta-
tions in rpoB (as previously reported for spontaneous 
mutants [32]), but were confirmed to be intron negative 
by PCR (data not shown). In contrast, experiments with 
the aadA marker consistently resulted in Specr, IncA-
null strains (the non-fusogenic phenotype was frequently 
observed at passage P3). Mutants were plaque isolated 
and a single clone, DFCT9 (incA::GII[aadA]), was cho-
sen for expansion and characterization. Intron insertion 
into incA was validated and mapped using PCR (results 
are shown in Fig.  2, reactions are described in Table  1) 
and the incA::GII(aadA) and wild type loci also were 
cloned for DNA sequencing analysis. The intron inserted 
in a sense orientation between base pairs 108 and 109 of 
the ORF as predicted by the TargeTron algorithm and as 
previously found with the identically targeted GII(bla) 
intron (p) [20].
After validating the aadA marker for mutagen-
esis, we sought to create a double-insertion mutant 
using the GII(bla) intron targeted to rsbV1 (pDFTT-
6bla) and the GII(aadA) intron targeted to incA. The 
rsbV1 gene encodes an anti–anti-sigma factor that is 
hypothesized to belong to a conserved partner switch-
ing mechanism in Chlamydia [33]. We first constructed 
the rsbV1::GII(bla) mutant (DFCT13) and verified the 
intron insertion using PCR (Fig. 3; Table 1) and sequenc-
ing of the rsbV1::GII(bla) locus. As predicted, the 
intron inserted into rsbV1 in an anti-sense orientation 
between base pairs 28 and 29 (sequencing data results 
are shown in Figure S3). DFCT13 was then transformed 
with pDFTT3(aadA) to create an rsbV1::GII(bla), 
incA::GII(aadA) double-insertion mutant, DFCT16. 
PCR was used to map both intron-insertion sites (Fig. 4; 
Table 1) and the rsbV1::GII(bla) and incA::GII(aadA) loci 
were sequenced. The point of insertions in the double 
mutant matched the insertion sites for the respective sin-
gle insertion mutants.
Following molecular validation of the strains, all 
mutants were further assessed for phenotypes via inclu-
sion morphology at 24  h post-infection using immuno-
fluorescence microscopy and production of IncA and 
RsbV1 (Figs. 5; 6, respectively). All mutants grew in the 
presence of the appropriate antibiotics and were inhib-
ited by antibiotics for which resistance markers were 
lacking. An anti-MOMP antibody was used as a marker 
Fig. 1 Assessment of intron stability in vivo using a mouse infec-
tion model. BALB/c mice were infected intravaginally with DFCT3 
(incA::GII[bla]) in the absence of ampicillin and swabs were taken at 3 
day intervals to measure EB titers (IFU/ml), panel a [19]. To measure 
intron-stability, swabs were used to infect mouse L2 cells in the 
absence of ampicillin and serially passaged to obtain DNA for incA 
PCR (reaction 1, Table 1) and to assess inclusion morphology. Repre-
sentative incA PCR results are shown in panel a. In panel b, represent-
ative phase contrast micrographs (×400) are shown for cells infected 
at an MOI of ~5 with the wild type strain or with an expansion sample 
from a day 27 post-infection swab. The red arrow highlights a wild 
type inclusion
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for C. trachomatis and an anti-CT223 antibody was used 
as a marker for the inclusion (CT223 is an inclusion 
membrane protein [34]). In the presence of ampicillin, 
strains lacking the bla marker presented as enlarged, 
aberrant RBs within inclusions that were mostly negative 
for the inclusion membrane protein CT223 (as seen for 
Fig. 2 PCR validation of DFCT9, an incA insertion mutant created using the GII(aadA) spectinomycin-selection cassette. EBs were transformed with 
pDFTT3aadA and serially passaged with spectinomycin selection. Mutants were plaque purified and a single plaque was expanded for PCR and 
phenotype analysis (shown in Figs. 5, 6). The insertion locus map is shown in panel a (DFCT3 is from [19] ) with the intron highlighted in red. The 
intron is inserted in a sense orientation to incA. The GII(aadA) intron in vector pDFTT3aadA was used to create the incA mutation in both DFCT9 and 
DFCT16 (Fig. 4). Expected PCR product sizes are listed in panel b. The primers used and reaction descriptions are listed in Table 1. PCR products were 
run on 0.8 % agarose gels, stained with ethidium bromide, and visualized with a UV light source. Molecular weight markers (kbp) are shown to the 
left of each gel. Images were inverted to improve contrast. PCR results are shown for the wild type strain, DFCT9, and pDFTT3aadA in panels c, d, 
and e, respectively
Table 1 PCR reactions used to map intron insertions in DFCT3, DFCT9, DFCT13, and DFCT16
Reaction Primers Target Notes
1 V1F–V1R rsbV1  Confirms intron insertion (primers flank insertion site)
2 incAF–incAR incA Confirms intron insertion (primers flank insertion site)
3 hyp08F–hyp08R cryptic plasmid  Confirms that transformation has not resulted in loss of the native, 
cryptic plasmid
4 incAF–GIIR Connects the 5′ region of incA to the intron Confirms intron insertion and orientation
5 incAR–GIIF Connects the 3′ region of incA to the intron Confirms intron insertion and orientation
6 GIIF–GIIR Intron Confirms intron presence
7 incAF–aadAR Connects incA to the aadA marker Confirms marker type
8 catF–catR Intron donor plasmid Confirms loss of intron donor plasmid
9 V1F–GIIF Connects the 5′ region of rsbV1 to the intron Confirms intron insertion and orientation
10 V1R2–GIIR Connects the 3′ region of rsbV1 to the intron Confirms intron insertion and orientation
11 blaR2–VIR Connects rsbV1 to the bla marker Confirms marker type
12 blaF1–blaR1 Marker Confirms presence of bla marker
13 aadAF–aadAR Marker Confirms presence of aadA marker
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the wild type strain and DFCT9 in Fig. 5a). Strains lack-
ing the aadA marker formed small, punctate inclusions 
lacking CT223-staining (wild type strain and DFCT13) 
in the presence of spectinomycin (Fig. 5a). Aberrant RBs 
are observed under certain stress conditions, including 
beta-lactam treatment, and are thought to be viable, non-
dividing bacteria [35–38]. Both IncA-null strains, DFCT9 
and DFCT16, formed multiple inclusions consistent with 
the role of IncA in inclusion fusion. IncA-null status of 
the mutants was further confirmed using anti-IncA west-
ern blot analysis (Fig.  6). No obvious phenotype altera-
tions were observed for the RsbV1-null strains compared 
to the wild type strain or the IncA-null strain (in the 
case of the double-mutant) under the conditions tested. 
Recent work by Thompson et  al. demonstrates that an 
RsbV1-null strain shows minor growth defects and tran-
scriptional differences that would not have been detected 
in our assay [39]. Western blot using an anti-RsbV1 anti-
body confirmed that the rsbv1 mutants DFCT13 and 
DFCT16 do not produce RsbV1 (Fig. 6).
Conclusions
Collectively, our results further expand the utility of 
the TargeTron system for mutagenesis in Chlamydia by 
allowing for: (1) complementation with existing shuttle 
vectors, (2) inactivation of multiple genes in the same 
bacterium and mutagenesis outside of the LGV sero-
var, and (3) use in vivo where long-term intron stability 
had not been previously assessed. The latter point is rel-
evant to other pathogens in which the TargeTron system 
is employed as it alleviates the need for experimental 
conditions that could lead to disruption of the normal 
microflora due to antibiotic administration. In addition, 
we validated aadA as a resistance marker in Chlamydia. 
As spectinomycin is not a recommended drug for treat-
ment of infections caused by Chlamydia spp., the aadA 
marker should be applicable as a selection marker across 
Chlamydia. Finally, the mutants created in this study will 
be useful for discerning the roles of incA and rsbV1 in 
chlamydial physiology and virulence.
Methods
Bacterial and Cell Culture Escherichia coli strain DH5α 
was used for all cloning procedures. E. coli were grown in 
either LB broth or on LB agar plates supplemented with 
antibiotics (100 μg/ml ampicillin, 100 μg/ml spectinomy-
cin, and/or 20 μg/ml chloramphenicol) at 30  °C. Mouse 
L2 fibroblasts were used for cell culture experiments and 
Fig. 3 PCR validation of DFCT13, an rsbv1 insertion mutant created using the GII(bla) ampicillin-selection cassette. EBs were transformed with 
pDFTT6bla and serially passaged with ampicillin selection. Mutants were plaque purified and a single plaque was expanded for PCR and phenotype 
analysis (Figs. 5, 6). The insertion locus map is shown in panel a with the intron highlighted in pink. The intron is inserted in an anti-sense orientation 
to rsbV1. DNA was isolated from EBs and used for PCR. Expected product sizes are listed in panel b and the primers used along with reaction notes 
are listed in Table 1. PCR products were separated and visualized as described for Fig. 2. PCR results are shown for the wild type strain, DFCT13, and 
pDFTT6bla in panels c, d, and e, respectively
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passage of C. trachomatis L2 434/Bu. Cells were grown 
in DMEM supplemented with 10 % FBS at 37 °C with 5 % 
CO2. For routine growth of C. trachomatis, cells were 
grown until confluent and then infected with EBs via cen-
trifugation at 545g for 1 hour. Chlamydia-infected cells 
were grown at 37 °C with 5 % CO2 in DMEM, 10 % FBS, 
0.2  μg/ml cycloheximide, and 1×  non-essential amino 
acids. EB stocks were titered using the inclusion form-
ing unit assay (IFU) and stored in sucrose phosphate-
buffered glutamic acid (SPG, 0.19 mM KH2PO4, 0.36 mM 
K2HPO4, 0.245 mM l-glutamic acid, 10.9 mM sucrose) at 
−80 °C. Strains created in this study and specific growth 
conditions are listed in supplementary Table 1.
Construction of the intron donor vectors pDFTT3aadA 
and pDFTT6bla The pDFTT3 vector (incA-targeted 
intron carrying the bla marker [20]) was used as the base 
vector for construction of pDFTT3aadA and pDFTT-
6bla (Figure S1). Phusion High-Fidelity PCR Master 
Mix (Thermo Scientific) was used for all PCR reactions 
and DNA was routinely analyzed using agarose gel elec-
trophoresis and ethidium bromide staining. Primers 
were used at a concentration of 0.5 μM. DNA isolation 
(plasmids, PCR products, and gel-purified fragments) 
was performed using the respective GeneJET DNA kit 
(Thermo Scientific). All DNA constructs were sequenced 
by Macrogen USA.
To create pDFTT3aadA, the aadA gene from pAM238 
[40] was PCR amplified with primers aadAF and aadAR 
(primer sequences are provided in supplementary 
Table 2). The PCR product was then digested with MluI 
and ligated into a similarly digested pDFTT3, effectively 
replacing the bla cassette with the aadA cassette (Figure 
S2). To create the rsbV1-targeted intron in pDFTT6bla, 
the rsbV1 sequence was analyzed for insertion sites using 
the Sigma-Aldrich TargeTron algorithm. The predicted 
insertion site (TCCCTTGTAAATGAAGGATGCCTG 
TTTGGC—intron—CTTGTTCTTCTTTCT, antisense 
orientation, Figure S3) had an E-value of 0.75 and a score 
of 8.51. To re-target the intron, primers rsbV1 IBS, rsbV1 
EBS1d, rsbV1 EBS2, and Univ were used in a PCR reac-
tion with pDFTT3 as template to create the modified tar-
geting region (PCR reaction conditions are specified in 
the TargeTron manual, Sigma-Aldrich). The PCR prod-
uct was then digested with BsrGI and HindIII and ligated 
into a similarly digested pDFTT3. All ligation products 
were transformed into E. coli DH5α and transformants 
were selected on LB agar plates with the appropriate 
antibiotics.
Fig. 4 PCR validation of DFCT16, an rsbv1 and incA dual-insertion mutant created using the GII(bla) and GII(aadA) cassettes. DFCT13 EBs were trans-
formed with pDFTT3aadA and serially passaged with spectinomycin selection. Mutants were plaque purified and a single plaque was expanded 
for PCR and phenotype analysis (Figs. 5, 6). The incA and rsbV1 insertion locus maps are shown in panel a. Expected PCR product sizes are listed in 
panel b and the primers used along with reaction notes are listed in Table 1. PCR products were separated and visualized as described for Fig. 2. PCR 
results are shown for the wild type strain and DFCT16 in panels c and d, respectively
Page 7 of 10Lowden et al. BMC Res Notes  (2015) 8:570 
Fig. 5 Growth phenotypes of DFCT9, DFCT13, and DFCT16 with and without ampicillin and/or spectinomycin. In panel a, L2 mouse cells were 
infected at an MOI ~5 with the wild type strain, DFCT9, DFCT13, or DFCT16 in the presence of no drug (top row), spectinomycin (second row from 
top), ampicillin (third row from top), or spectinomycin and ampicillin (fourth row from top). Resistance profiles and strain types are listed at the top of 
each row. Samples were processed for immunofluorescence microscopy at 24 h post infection. Cells were probed with anti-MOMP (green, marker 
for bacteria), anti-CT223 (red, inclusion membrane protein), and stained with DAPI (blue, DNA). Images were acquired at ×630 under oil-immersion 
and only the composite images are shown. In panel b, bla and aadA specific PCR was used to detect the resistance marker present in each strain. 
PCR products were visualized as described in Fig. 2
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Construction of C. trachomatis mutants Transforma-
tion of C. trachomatis and mutant selection with the 
GII(bla) vector was performed as described in John-
son and Fisher to create DFCT13 (rsbV1:GII[bla]) [20]. 
When using the GII(aadA) vector to create DFCT9 
(incA::GII[aadA]) and DFCT16 (incA::GII[aadA], 
rsbV1::GII[bla]), spectinomycin was substituted for 
ampicillin and was used at 500  μg/ml for all selection 
steps. After multiple rounds of selection, transformants 
were titered and clones were obtained using a standard 
plaque assay. Plaque isolates were expanded in cell cul-
ture, tested for mycoplasma contamination using PCR, 
and stored in SPG. DFCT16 was created by transform-
ing DFCT13 with pDFTT3aadA under spectinomycin 
selection.
All recombinant DNA experiments were performed 
in accordance with NIH section III-D-1-a and were 
approved by the Southern Illinois University recombi-
nant DNA committee.
Molecular analysis of DFCT9, DFCT13, and DFCT16 
Genomic DNA was isolated using the DNeasy Blood & 
Tissue kit (Qiagen) and PCR was performed using Phu-
sion High-Fidelity PCR Master Mix. PCR reactions were 
run with either 50 ng of genomic DNA or 1 ng of plasmid 
DNA as template. PCR products were separated on 1 % 
agarose gels, stained with ethidium bromide, and visual-
ized using UV transillumination. The primer pairs used 
are listed in Table 1.
For DNA sequencing, the incA and rsbV1 wild type and 
intron-disrupted loci were PCR amplified using primers 
incAF/incAR or V1F/V1R, respectively. PCR products 
were ligated into the pJET vector (Life Technologies) and 
transformants were grown for plasmid DNA isolation. 
Plasmid-inserts were sequenced by Macrogen USA using 
the primers pJET1_2F (CGACTCACTATAGGGAGAGC 
GGC) and pJET1_2R (AAGAACATCGATTTTCCATGG 
CAG). Sequence analysis was performed using Clone 
Manager (Scientific and Educational Software) and 
sequences were compared with the C. trachomatis L2 
434/Bu genome (accession number: NC_010287).
Phenotype analysis of DFCT9, DFCT13, and DFCT16 
Confluent monolayers of L2 mouse cells grown in 24 
well dishes (with or without glass coverslips) were mock-
infected or infected using centrifugation with the wild 
type strain, DFCT9, DFCT13, or DFCT16 diluted in 
DMEM to an MOI of  ~5. Following centrifugation, the 
medium was replaced with DMEM, 10 % FBS, 0.2 μg/ml 
cycloheximide, 1x non-essential amino acids, and antibi-
otics (5 μg/ml ampicillin and/or 500 μg/ml for spectino-
mycin). Infected cells were incubated at 37 °C, 5 % CO2.
Phase contrast light micrographs, immunofluorescent 
micrographs, and protein samples for western blot were 
obtained at 24  h post-infection. For immunofluores-
cence microscopy, cells were fixed and then probed with 
mouse monoclonal anti-CT223 antibodies (Dan Rockey, 
Oregon State University, 1:10) followed by goat anti-
mouse IgG-Texas red conjugated antibodies (1:1000). 
Samples were then probed with FITC-conjugated mouse 
anti-MOMP antibodies (1:1000) and stained with DAPI 
to detect DNA. Fluorescent images were acquired using 
a Leica DM4000 fitted with a QImaging QiClick Mono 
camera and composite images were built using QImaging 
Software.
For western blot analysis, non-antibiotic treated sam-
ples were washed with phosphate buffered saline followed 
by addition of Laemmli buffer. Laemmli-treated samples 
were heated for 5 min at 95 °C and loaded into 12 % SDS-
PAGE gels. Following electrophoresis, proteins were 
transferred to nitrocellulose for western blotting. Blots 
were blocked with 5 % milk Tris buffered saline (MTBS) 
and incubated overnight at 4 °C with either mouse anti-
MOMP (Abcam, 1:1000), anti-IncA, anti-CT223 (both 
provided by Dan Rockey, Oregon State University, 1:250), 
or rabbit polyclonal anti-RsbV1 (this study, raised against 
the RsbV1 peptide KVFDSVNEALQALAKENS, per-
formed by Thermo-Scientific Pierce, 1:200) antibodies 
diluted in MTBS. Blots were washed with 0.05 % tween 
Tris buffered saline (TTBS) and then incubated with 
Fig. 6 Western blot detection of IncA and RsbV1 in DFCT9, DFCT13, 
and DFCT16. Protein samples from cells infected in the absence 
of drug were run on SDS-PAGE, transferred to nitrocellulose, and 
probed with either anti-MOMP, anti-CT223, anti-IncA, or anti-RsbV1 
antibodies. The anti-MOMP and anti-CT223 antibodies were used as 
controls to confirm the presence of bacteria and inclusion proteins, 
respectively, in each sample. Blots were then probed with HRP-
conjugated secondary antibodies and visualized using a chemilu-
minescent substrate. Molecular weight markers (kDa) are shown to 
the left of each blot and the primary antibody used along with the 
predicted protein size are listed at the bottom of each blot. Contrast 
was adjusted (universally over the entire blot image) for the RsbV1 
blot (to highlight band intensity). The (i) and (r) notations indicate the 
mutation(s) carried by the strain (incA and/or rsbV1)
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HRP-conjugated anti-mouse IgG or anti-rabbit IgG 
antibodies diluted in MTBS. Prior to incubation with 
Immobilon Western Chemiluminescent HRP substrate 
(Millipore) the blots were washed with TTBS.
Assessment of intron stability in  vivo Balb/C mice 
(8-weeks-old) were purchased from Harlan Laborato-
ries (Indianapolis, IN). Seven days prior to infection 
with DFCT3 (incA::GII[bla]), mice were injected subcu-
taneously with 2.5  mg of progesterone (Depo-Provera, 
UpJohn), [41]. Five mice were then challenged intravagi-
nally with 3x106 IFU using a sterile pipette tip as previ-
ously described. No antibiotics were administered to the 
mice throughout the course of infection. Genital swabs 
were performed at 3 day intervals post infection and were 
used to measure EBs via the IFU assay. Swab samples 
also were used to verify intron presence using PCR and 
inclusion phenotype. To obtain enough material for these 
assays, swab samples were serially passaged in L2 mouse 
cells without ampicillin. All animal procedures were 
approved by the University of Arkansas Institutional Ani-
mal Care and Use Committee.
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